Patent
Stable composition of interleukin-2
TLDR
In this paper, an interleukin-2 composition which comprises human serum albumin, a reducing compound or a combination thereof is adjusted as showing pH of 3 to 6 as a solution.Abstract:
The present invention provides an interleukin-2 composition which comprises human serum albumin, a reducing compound or a combination thereof and is adjusted as showing pH of 3 to 6 as a solution. The composition of the present invention is characterised in that the interleukin-2 activity is lost little during storage and in the process of freezing and lyophilizationread more
Citations
More filters
Patent
Method for administering interleukin-2
TL;DR: In this paper, a composite polyer matrix comprising interleukin-2 in an appropriate polymer was presented for intracranial or other implantation and a method for implanting the material was described.
Patent
Formulations for IL-11
TL;DR: In this paper, the authors present novel compositions and methods for obtaining concentrated preparations of IL-11 and formulations of IL11 suitable for storage and administration, and present a method for extracting concentrated IL11 from IL11 formulations.
Patent
Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
TL;DR: In this article, stable pharmaceutical compositions suitable for parenteral administration to animals or humans are prepared comprising a therapeutically effective amount of a recombinant interleukin-2 (IL-2) protein dissolved in an inert carrier medium comprising one or more biocompatible non-ionic polymeric detergents which act as solubilizer/stabilizers for the claimed formulations.
Patent
Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
TL;DR: A parenteral medicinal composition which contains a humanized monoclonal antibody fragment, a nonionic surfactant and sugars and has a weakly acidic pH value is described in this paper.
Patent
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
TL;DR: Muteins of biologically active proteins such as IFN-β and IL-2 in which cysteine residues that are not essential to biological activity have been deleted or replaced with other amino acids to eliminate sites for intermolecular crosslinking or incorrect intramolecular disulfide bridge formation.
References
More filters
Patent
Pharmaceutical compositions of microbially produced interleukin-2
TL;DR: A sterile, stable lyophilized formulation of selectively oxidized microbially produced recombinant IL-2 is described in this article, which is suitable for reconstitution in aqueous injections for parenteral administration.
Journal Article
The purification and properties of human T cell growth factor.
James W. Mier,R C Gallo +1 more
TL;DR: Human T cell growth factor has been purified more than 800-fold from serum-free lymphocyte conditioned media by utilizing ion exchange chromatography with DEAE-Sepharose, gel filtration with Ultrogel AcA54, and preparative SDS-polyacrylamide gel electrophoresis.
Patent
Homogeneous human interleukin 2
TL;DR: In this paper, human interleukin 2 (IL-2) derived from induced human malignant cells has been purified to homogeneity using multiple high performance liquid chromatography (HPLC) steps.
Patent
Highly purified protein, production and use thereof
TL;DR: In this article, a substantially pure non-glycosylated human interleukin-2 protein having a specific activity of not less than 10 U/mg was obtained by growing a transformant carrying a DNA having a base sequence coding for human IL2 in the culture broth, and subjecting the thus obtained human IL 2-containing liquid to a purification process comprising a hydropholic column chromatography.
Patent
A method for producing non-glycosylated human interleukin-2 protein
TL;DR: A substantially pure non-glycosylated human interleukin-2 protein having a specific activity of not less than 10 U/mg is obtained by growing a transformant carrying a DNA having a base sequence coding for human IL-2 to cause production and accumulation of human ILI-2 in the culture broth, and subjecting the thus obtained human ILII-containing liquid to a purification process based on hydropholic column chromatography as discussed by the authors.